comparison of lc/ms/ms and gc/msd analyses of pesticide...
TRANSCRIPT
PO
93
920
312
_W_1
Comparison of LC/MS/MS and GC/MSD Analyses of Pesticide Residues in Food Products when Using the QuEChERS Sample Preparation Technique
Monika Kansal, A. Carl Sanchez, Michael Rummel, and Art Dixon
Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA
QuEChERS, an acronym for Quick, Easy, Cheap, Effective, Rugged, and Safe, is a sample preparation procedure commonly used for the extraction and cleanup of multiple pesticide residues from food and agricultural products. This relatively simple procedure provides extracts suitable for both LC/MS and GC/MS analyses.
In this study the results obtained when analyzing the same extracts from multiple food products using both GC/MSD and LC/MS/MS are presented and compared. The relative strengths of each instrument platform are highlighted and considerations for choosing the most appropriate platform are presented.
Introduction
Results and Discussion
Iceberg Lettuce ExtractionThe total number of possible failures is 125 •100%passingisdifficulttoachieve •Themostproblematicanalytesarediscussedinthisstudy
Analytes LC/MS LC/MS LC/MS GC/MS GC/MS GC/MS
Recovery % RSD Linearity Recovery %RSD LinearityAtrazine 85 2 1.000 105 5% 1.000Azoxystrobin 88 3 0.999 109 11% 0.994Bifenthrin N/A N/A N/A 108 6% 0.997
Carbaryl 94 3 0.999 112 8% 0.999Chlorothalonil N/A N/A N/A 103 7% 0.999Chlorpyrifos 86 6 0.998 99 10% 0.946Chlorpyrifos-methyl 82 3 0.996 115 5% 0.988Cyprodnil 89 2 0.999 107 5% 0.999Dichlorvos 34 37 0.768 106 6% 0.998Endosulfan sulfate N/A N/A N/A 110 5% 0.999Ethion 95 3 0.999 106 7% 0.999Imazalil * 92 3 1.000 87 10% 0.984Imidacloprid 93 3 1.000 N/A N/A N/AKresoxim-methyl 94 2 0.997 107 6% 0.993Linuron 93 3 0.999 N/A N/A N/AL-Cyhalothrin N/A N/A N/A 110 8% 0.997Methamidophos * 74 3 0.999 113 9% 0.995Methomyl 87 2 1.000 N/A N/A N/Ao,p-DDD N/A N/A N/A 100 5% 0.998o-phenolphenyl N/A N/A N/A 103 5% 1.000Permethrins N/A N/A N/A 112 8% 0.998Procymidone N/A N/A N/A 107 5% 0.999Pymetrozine 69 4 1.000 N/A N/A N/ATebuconazole 91 3 0.999 105 7% 0.998Thiabendazole * 95 2 0.997 96 13% 0.986Tolyfluanid 90 2 0.997 95 15% 0.992Trifluralin N/A N/A N/A 101 5% 0.996
Recovery • LC/MS- All analytes (18) passed Association of Analytical Chemists AOAC criteria except Dichlorvos •AllcalculationsbasedonExternalStandardization(ESTD) •PymetrozineislowasexpectedbyAOACmethod • GC/MS- All analytes (23) showed good recovery •AllcalculationsbasedonInternalStandardization(ISTD)% RSD for sample replicates • LC/MS- All analytes passed AOAC criteria except Dichlorvos •Basedon5samplereplicates • GC/MS- All analytes passed AOAC criteria •Basedon5samplereplicatesCorrelation coefficient (linearity) • LC/MS - All analytes passed AOAC criteria except Dichlorvos •AllcalculationsbasedonESTD • GC/MS - Linearity criteria was low for a few analytes •Sensitivityformethamidophos,imazalilandthiabendazolewasinadequateatlow levels
Spinach ExtractionPigmentedmatricesrequiregraphitizedcarbonblack(GCB) •GCBisknowntoadsorbplanarmolecules* •ProcymidonesufferedlossinGC/MSduetomatrixco-elution** •Optimizedanalysisconditionsasdeterminedinthisstudy
Analytes LC/MS LC/MS LC/MS GC/MS GC/MS GC/MS
Recovery %RSD Linearity Recovery %RSD LinearityAtrazine 73 6 0.998 95 3% 0.999Azoxystrobin 88 5 0.999 117 6% 0.996Bifenthrin N/A N/A N/A 92 4% 0.999Carbaryl 73 6 0.999 87 9% 0.999Chlorothalonil * N/A N/A N/A 26* 9% 0.999Chlorpyrifos 63 5 0.997 80 5% 0.999Chlorpyrifos-methyl 75 3 0.997 75 2% 0.999Cyprodnil * 14* 6 0.998 17* 6% 0.999Dichlorvos N/A N/A N/A 81 8% 0.999Endosulfan sulfate N/A N/A N/A 105 6% 0.999Ethion 83 6 0.996 102 4% 0.997Imazalil 82 3 0.998 N/A N/A N/AImidacloprid 89 5 0.999 N/A N/A N/AKresoxim-methyl 97 5 0.996 98 5% 0.999Linuron 74 5 0.997 N/A N/A N/AL-Cyhalothrin N/A N/A N/A 108 9% 0.999Methamidophos 87 6 0.999 N/A N/A N/AMethomyl 85 6 0.999 N/A N/A N/Ao,p-DDD N/A N/A N/A 102 4% 0.998o-phenolphenyl N/A N/A N/A 94 4% 0.998Permethrins N/A N/A N/A 95 4% 0.997Procymidone** N/A N/A N/A 46** 33% 0.999Pymetrozine * 10* 7 0.997 N/A N/A N/ATebuconazole 81 4 0.997 83 3% 0.992Thiabendazole * 12* 6 1.000 N/A N/A N/ATolyfluanid 84 8 0.993 88 7% 0.999Trifluralin N/A N/A N/A 93 3% 0.997
Thiabendazole* Cyprodnil*Pymetrozine*
LC/MS - Challenges and Solutions
Problematic AnalytesInjection solvent mismatch •AOACinjectionsolvent25%Acetonitrile(ACN)peakdistortion Earlyelutersgavesplitpeaks(pymetrozine,methamidophos,thiabendazole) •Reducedsolventstrength-sampleprecipitation FiltermembranesabsorbanalytestovariousdegreesMobile Phase – Limited flexibility •Increaseinitial%organic-earlyelutersnotretained Earlyelutersunretainedinsomepublishedpapers •Decreaseinitial%organic–reconstitutionsolventmismatchMatrix effects •Eachanalyterespondsdifferentlytomatrixinterferences Oneinternalstandardforallanalytesdoesnotgivereliableresults
LC/MS Injection Solvent - Peak Distortion
Earlyelutingpeaksdistortedwith25%acetonitrileinjectionsolvent(assuggestedbyAOAC)
•Initialmobilephase:5mMFormicAcid(FA)in25%methanol(MeOH)
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 min0.00
500.001000.001500.002000.002500.003000.003500.004000.004500.005000.005500.006000.006500.007000.007500.008000.008500.009000.009500.00
1.00e41.04e4
Inte
nsity
, cp
s
3.12
3.5519.4318.0014.00 34.2516.766.26 20.591.29 7.14 33.815.26 13.7911.75 21.68 35.449.08 23.73 30.04 39.4036.7328.69 42.6227.19
Pymetrozine,split peaks
Sample dissolved in 25 % ACN 5mM FA
As per AOAC
Ap
p ID
20
672
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 min111 221 331 442 552 662 772 882 992 1102 1213 1323 1433 1543 1653 1763 1873 1984 2094 2204 2314
050
100150200250300350400450500550600650700750800850900950
1000
Inte
nsity
, cp
s
3. 86
35. 266.1434.338. 08 11.33
7.521. 16
14.782.32 5.76 15. 8711.89 35.399.90 24.79 36. 95
38.4233.2529. 3928.00 40. 1323. 3018. 16 22.23 30.76
28. 1420.47
Methamidophos
Sample dissolved in 25 % ACN 5mM FA
As per AOAC
Ap
p ID
20
66
8
Solution
Challenge
Reducedsolventstrength–25%MeOH
•Peaksplittingissueresolved
•Precipitation
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 min0.0
2000.04000.06000.08000.0
1.0e41.2e41.4e41.6e41.8e42.0e42.2e42.4e42.6e42.8e43.0e43.2e43.4e43.6e43.8e44.0e44.2e4
Inte
nsity
, cp
s
3.45
Pymetrozine
Sample dissolved in 25 % MeOH 5mM FA
Ap
p ID
20
674
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 min111 221 331 442 552 662 772 882 992 1102 1213 1323 1433 1543 1653 1763 1873 1984 2094 2204 2314
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
Inte
nsity
, cp
s
3.82
11.2411.8410.739.03 24.2416.3113.536.86 35.28
Methamidophos
Sample dissolved in 25 % MeOH 5mM FA
Ap
p ID
20
673
LC/MS Injection Solvent – Sample Precipitation(Filtration)
Matrixcomponentsprecipitatewhen25%methanolisused5ng/gCalStandardpreparedin25%Methanol5mMFormicacid •Allfiltermembranesabsorbanalytes–differentforeachfilter
•Belowisthe%losswithfiltrationforthemostproblematicanalytes
Samplesinjectedwithout filtration(centrifuged)
•Noproblemswithcolumn fouling
% Loss withGHP �lter
% Loss withNylon �lter
% Loss withRC �lter
% Loss withPTFE �lter
% Loss withPTVDF �lter
% L
oss
Chlorpyrifos
EthionImazalil 1
Methamidophos 2
Thiabendazole 1
D10-Parathion
% Loss on Filtration-5 ng/g cal standard
Solution
Challenge
LC/MS – Limited Flexibility of Mobile Phase
2 4 6 8 10 12 14 16 18 20 22 24 min114 227 341 454 567 680 793 906 1020 1133 1246 1359
0. 00500. 00
1000. 001500. 002000. 002500. 003000. 003500. 004000. 004500. 005000. 005500. 006000. 006500. 007000. 007500. 008000. 008500. 009000. 009500. 00
1. 00e41. 05e41. 10e41. 15e41. 20e4
Inte
nsity
, cp
s
1. 79
Pymetrozine unretained(to=1.8 mins ), RT=1.79 mins
Column: Prodigy™ ODS-3 5 µm
Dimensions: 150 x 3.0 mm Mobile Phase A: Water with 0.1 % Formic acid
B: Acetonitrile with 0.1 % Formic acid
Gradient: 30 to 100 % B in 8 min, 5.5 min final hold at 100 % B
Flow Rate: 0.3 mL/min
Instrument: MS: API4000™ (ESI+), LC: Agilent® 1200
Sample solvent: 40 % ACN in water with 0.4 % Acetic acid
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 min114 227 341 454 567 680 793 906 1020 1133 1246 1359 1472 1585 1699 1812 1925 2038 2151 2265 2378
0
50010001500200025003000350040004500500055006000650070007500800085008860
Inte
nsity
, cp
s
3. 04
3. 51
Pymetrozine retained RT=3.04 mins, but splitting
Mobile phase/sample solvent mismatch (AOAC 2007)
Column: Luna® C18(2) 3 µm,
Dimensions: 150 x 3.0 mm
Mobile Phase A: Water with 5 mM Formic acidB: Methanol with 5mM Formic acid
Gradient: 25 to 90 % B in 15 mins, 15mins final hold at 100 % B
Flow Rate: 0.3 mL/min
Instrument: MS: API4000™ (ESI+), LC: Agilent 12000
Sample Solvent: 25 % ACN in water with 0.25 % Acetic acid
Different mobile phase conditions (JCA Article (2010))
Ap
p ID
20
675
Ap
p ID
20
670
Effect of Matrix Interference in QC SampleLC/MS Analysis for Lettuce
Carbaryl % RSD=2 %
Ratio IS/TPP % RSD=17 %
Cyprodnil % RSD=2 %
D10-IS % RSD=17 %
TPP% RSD=2 %
Matrix interferences affect the internal standard (d10-parathion as per AOAC) differently than analytes
•%RSDISTD>>%RSDanalyte->matrixeffectswithISTD
•StablelabelISTDforallanalytesnotgenerallyusedinmulti-residuemethods(GC/MS)
• Standard practice for LC/MS due to matrix effects
LC/MS Matrix Effects
Effect of Matrix Interference in QC SampleLC/MS Analysis for Lettuce
Carbaryl % RSD=2 %
Ratio IS/TPP % RSD=17 %
Cyprodnil % RSD=2 %
D10-IS % RSD=17 %
TPP% RSD=2 %
GC/MS - Challenges and Solutions
Problematic AnalytesOverall fewer problems than LC/MS Matrix interferences •Co-elutingmatrixcomponents •SomematricesmoreproblematicthanothersChromatographic degradation (inlet fouling, losses) •Accumulationofmatrixcomponents •Poorpeakshape •Reducedsensitivity
GC/MS Interferences - Methamidophos
3.50 3.52 3.54 3.56 3.58 3.60 3.62 3.64 3.66 3.68 3.70 3.72 3.74 3.76 3.78 3.80 3.82 3.84 min0
100020003000400050006000700080009000
10000110001200013000
Interference
Methamidophos
3.50 3.52 3.54 3.56 3.58 3.60 3.62 3.64 3.66 3.68 3.70 3.72 3.74 3.76 3.78 3.80 3.82 min0
2000
4000
6000
8000
10000
12000
14000
Interference
Early eluter co-elutes with interference
•AnalyzebyLC/MSforoptimumresults
50 ng/g Cal standard (apple extract)
Blank(appleextract)
Ap
p ID
20
676
Ap
p ID
20
671
GC/MS Inlet Losses - Imazalil in Different Matrices
11.60 11.80 12.00 12.20 12.40 12.60 12.80 13.00 13.20 13.40 min0
50100150200250300350400450500550600650700750800850900950
Imazalil
11.60 11.80 12.00 12.20 12.40 12.60 12.80 13.00 13.20 13.40 min
50100150200250300350400450500550600650700750800850900950
Imazalil
Accumulation of matrix components in inlet liner leads to poor peak shape and reduced sensitivity
•AnalyzebyLC/MSforoptimumresults
Lettuce extract 50 ng/g Cal standard
Spinach extract 50 ng/g Cal standard
Advantages of LC/MS Over GC/MS Analysis
Methamidophos, imazalil and thiabendazole show better performance with LC/MS than GC/MS •BetterpeakshapeinLC/MS
•HighersignalintensityinLC/MS
•Goodlinearityand%RSDwithLC/MS
Advantages of LC/MS GC/MS Analysis •Analyze by LC/MS for optimum results
Thiabendazole using LC/MS and GC/MS
Methamidophos using LC/MS and GC/MS
5.2 5.4 5.6 5.8 6.0 6.2 6.4 6.6 6.8 7.0 7.2 7.4 7.6 7.8 8.0 min0.0
2000.04000.06000.08000.01.0e41.2e41.4e41.6e41.8e42.0e42.2e42.4e42.6e42.8e43.0e43.2e43.4e43.6e43.8e4
Inte
nsity
, cp
s
6.40
ThiabendazoleLC/MS 5 ng/g (lettuce extract)
GC/MS 5 ng/g (lettuce extract)
10.60 10.80 11.00 11.20 11.40 11.60 11.80 12.00 12.20 12.40 min
102030405060708090
100110120130140150160170180190
Thiabendazole
3.50 3.52 3.54 3.56 3.58 3.60 3.62 3.64 3.66 3.68 3.70 3.72 3.74 3.76 3.78 min0
100020003000400050006000700080009000
10000110001200013000140001500016000170001800019000
Interference
Methamidophos
1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 11.0 12.0 13.0 14.0 15.0 16.0 min0.0
5000.01.0e41.5e42.0e42.5e43.0e43.5e44.0e44.5e45.0e45.5e46.0e46.2e4
Inte
nsity
, cp
s
3.77
MethamidophosLC/MS 100 ng/g (lettuce extract)
GC/MS 100 ng/g (lettuce extract)
Advantages of GC/MS Analysis Over LC/MS AnalysisInternal standardization possible •Ingeneral,GC/MSdoesnotsufferfromcompoundspecificmatrixeffectsSolubility •Nosolubilityproblems,allanalytesaresolubleintolueneandacetonitrileDramatically improved sensitivity for procymidone vs. LC/MS (no fragmentation with CID)Dichlorvos shows reproducible results in GC/MS •LC/MSresultsverypoor
Internal Standardization
Carbaryl % RSD=7 %
Ratio IS/TPP % RSD=14 %
Cyprodnil % RSD=6 %
D10-IS % RSD=8 %
TPP% RSD=7 %
GC/MS Analysis
Carbaryl % RSD=2 %
Ratio IS/TPP % RSD=17 %
Cyprodnil % RSD=2 %
D10-IS % RSD=17 %
TPP% RSD=2 %
LC/MS Analysis
Plot of D10-Parathion(internal standard) GC/MS and LC/MS/MS •InGC/MSmatrixgenerallydoesnotaffectionization • In LC/MS, co-elutingmatrix components affect ionizationof ISTDdifferently than analytes
•%RSDISTD>>%RSDanalyte->matrixeffectswithISTD
Effect of matrix interferences in lettuce QC samples
Analyte results using both GC/MS and LC/MS techniques
Dichlorvos improved performanceDichlorvosshowssignificantmatrixeffectsinLC/MS •ItfailedallcriteriainLC/MSbutpassedallinGC/MS •AnalyzebyGC/MSforoptimumresults
Analytes LC/MS-Lettuce LC/MS-Lettuce LC/MS-Lettuce GC/MS-Lettuce GC/MS-Lettuce GC/MS-Lettuce
Recovery % RSD Linearity Recovery % RSD LinearityAtrazine 85 2 1.000 105 5% 1.000Azoxystrobin 88 3 0.999 109 11% 0.994Carbaryl 94 3 0.999 112 8% 0.999Chlorpyrifos 86 6 0.998 99 10% 0.946Chlorpyrifos-methyl 82 3 0.996 115 5% 0.988Cyprodnil 89 2 0.999 107 5% 0.999Dichlorvos 34 37 0.768 106 6% 0.998Ethion 95 3 0.999 106 7% 0.999Imazalil 92 3 1.000 87 10% 0.984Kresoxim-methyl 94 2 0.997 107 6% 0.993Methamidophos 74 3 0.999 113 9% 0.995Tebuconazole 91 3 0.999 105 7% 0.998
Thiabendazole 95 2 0.997 96 13% 0.986Tolyfluanid 90 2 0.997 95 15% 0.992
Conclusions
Results for all analytes met AOAC performance expectations by carefully optimizing analysis conditionsMost appropriate platform selected for each analyte. •Besttechnique,GCorLC,isanalytespecific •Methamidophos,imazalilandthiabendazole-bestresultswithLC/MS •Dichlorvosandprocymidone-bestresultswithGC/MSInjection solvent and solubility •LC/MS-reconstitutesampleswith25%MeOHwithoutfiltering •GC/MS-nosolubilityproblemsMatrix interferences •ExternalstandardizationforLC/MSanalysis(ifnostablelabelISTDs) •InternalstandardizationforGC/MSanalysis
TrademarksLuna is a registered trademark, and Prodigy is a trademark of Phenomenex. AgilentisaregisteredtrademarkofAgilentTechnologies.API4000isatrademarkofABSCIEXpteLtd.ABSCIEXisbeingusedunderlicense. DisclaimerPhenomenexisnotaffiliatedwithAgilentTechnologies.Comparativeseparationsmaynotberepresentativeofallapplications.
© 2012 Phenomenex, Inc. All rights reserved.